Contrasting bluebird bio (BLUE) & Heat Biologics (HTBX)

bluebird bio (NASDAQ: BLUE) and Heat Biologics (NASDAQ:HTBX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for bluebird bio and Heat Biologics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
bluebird bio 2 8 12 0 2.45
Heat Biologics 0 0 2 0 3.00

bluebird bio presently has a consensus price target of $196.26, indicating a potential downside of 11.11%. Heat Biologics has a consensus price target of $22.50, indicating a potential upside of 956.34%. Given Heat Biologics’ stronger consensus rating and higher probable upside, analysts plainly believe Heat Biologics is more favorable than bluebird bio.


This table compares bluebird bio and Heat Biologics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
bluebird bio -947.42% -28.09% -23.00%
Heat Biologics -782.32% -153.27% -75.49%

Insider and Institutional Ownership

78.0% of Heat Biologics shares are held by institutional investors. 3.9% of bluebird bio shares are held by company insiders. Comparatively, 8.7% of Heat Biologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares bluebird bio and Heat Biologics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
bluebird bio $35.43 million 311.33 -$335.64 million ($7.66) -28.81
Heat Biologics $1.51 million 6.71 -$11.84 million ($3.90) -0.55

Heat Biologics has lower revenue, but higher earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Heat Biologics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

bluebird bio has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500. Comparatively, Heat Biologics has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.


Heat Biologics beats bluebird bio on 7 of the 13 factors compared between the two stocks.

About bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.

About Heat Biologics

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with's FREE daily email newsletter.

Leave a Reply